Insider buying last 90 days
No open-market insider purchases were filed for TECH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Bio-Techne's week centered on quarterly results and a pending acquisition. The company's first-quarter fiscal 2027 net sales rose 5% to $299.71 million, though net earnings declined to $28.29 million from $38.19 million, with diluted EPS of $0.18. A separate earnings report showed EPS of $0.42 against an estimate of $0.45, with revenue of $292.7 million short of the $293.03 million consensus. The board declared a quarterly dividend of $0.08 per share, payable 23 November 2026, contingent on the pending transaction with Merck KGaA not closing by 13 November 2026. Commentary also noted the stock trading above estimated intrinsic value on a discounted cash flow basis.
Shares closed at $72.83, up 0.1%, sitting above both the 50-day average of $72.49 and the 200-day average of $63.25, with the 50-day above the 200-day. The GekkoIndex reads 51.7, placing it in the Neutral zone, down 2.7 over five sessions. Price stands 24% above Gekko Fair Value of $58.72.
The next earnings date falls on 2 February 2027, 84 days out, beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. One billionaire holder and one trailblazer holder are recorded. Seasonally, the next 20 trading days have averaged a 1.8% gain over 5 years, positive in 3 of them. Analyst coverage from 4 firms shows 0 buy, 3 hold, and 1 sell, with a consensus target of $70.50.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Bio-Techne scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Above 50 and 200-day
Close $72.80 is above the 50-day ($72.53) and 200-day ($63.38) averages, and the 50-day is above the 200-day.
See the chart53.1, Neutral
Reading 53.1 is in the Neutral zone.
See the GekkoIndex23.4% above
Price is 23.4% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 79 days
Next report Feb 2, 2027, 79 days away — outside a typical 20-trading-day hold.
See earnings+3.1% on average
From this point in the calendar, the next 20 trading days averaged +3.1% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Bio-Techne closed at $72.80 on Nov 13, 2026, +18.6% over the past year, inside a 52-week range of $43.20 to $72.88.
Use the left and right arrow keys to read daily values.
Put TECH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Bio-Techne makes and sells reagents, instruments, and services used across life science research, diagnostics, and bioprocessing work. It is recognized for its biological reagents such as cytokines, growth factors, antibodies, and cell selection tools, along with proteomic instruments built for automated western blot and multiplexed ELISA testing.
The company is structured into two segments. Its Protein Sciences segment supplies reagents and analytical instruments applied to research, diagnostics, and cell and gene therapy work, including protein quantification tools for biological fluids. Its Diagnostics and Genomics segment produces diagnostic controls, calibrators, and assays for regulated diagnostic markets, along with exosome-based molecular diagnostics, spatial genomic and tissue biopsy assays, and products used in genetic carrier screening, oncology diagnostics, hematology, blood chemistry, gases, and coagulation testing.
Bio-Techne was formerly named Techne Corporation before taking its current name in November 2014, and it was incorporated in 1976. It is headquartered in Minneapolis, Minnesota, and its shares are listed on the NASDAQ under the ticker TECH.
Bio-Techne’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.1, in the Neutral zone, up 0.8 points over five sessions.
Up 0.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +0.9% | +3.3% | ||
| Accumulation | 245 | +1.1% | +3.2% | ||
| Neutral (current zone) | 376 | −0.4% | −0.8% | ||
| Distribution | 37 | −0.2% | −3.6% | ||
| Selling | 6 | Too few readings yet | |||
Average TECH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Bio-Techne trades 23.4% above Gekko Fair Value of $59.01, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Bio-Techne shares are worth, recalculated every trading day.
$59.01
Gekko Fair Value, Nov 14, 2026
23.4% Overvalued
At the end of Aug 2026 the price was 39.3% above the estimate.
No open-market insider purchases were filed for Bio-Techne, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for TECH in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in TECH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Bio-Techne has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold TECH.
Bio-Techne reports on Feb 2, 2027, before the open (79 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 2, 2027
Expected before the open, 79 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 12, 2026 | $0.52 est $0.52 | $321.2M est $314.6M | 0.0% |
| May 6, 2026 | $0.00 est $0.54 | $311.4M est $316.1M | −10.2% |
| Feb 4, 2026 | $0.46 est $0.43 | $295.9M est $290.5M | +1.9% |
| Nov 5, 2025 | $0.42 est $0.42 | $286.6M est $291.3M | −4.8% |
| Aug 6, 2025 | $0.53 est $0.50 | $317.0M est $294.6M | −8.2% |
| May 7, 2025 | $0.56 est $0.51 | $316.2M est $325.5M | +4.3% |
| Feb 5, 2025 | $0.42 est $0.39 | $297.0M est $317.5M | +3.4% |
| Oct 30, 2024 | $0.42 est $0.38 | $289.5M est $280.3M | +4.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Bio-Techne is $70.50, −3.2% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Evercore ISI | $73 | +0.3% |
| Nov 9 | RBC Capital | $73 | +0.3% |
| Oct 26 | Argus Research | — | — |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Bio-Techne averaged +3.1% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.4% | 2 of 5 |
| Next 10 trading days | 0.0% | 2 of 5 |
| Next 15 trading days | −0.8% | 2 of 5 |
| Next 20 trading days | +3.1% | 3 of 5 |
| Next 30 trading days | +3.8% | 2 of 5 |
For scale, TECH’s typical 20-trading-day move in either direction is about 6.6%.
Bio-Techne’s market cap is $11.44B, with a P/E ratio of 66.8 and revenue of $1.23B over the last twelve months.
Coverage of Bio-Techne this week reads neutral: 1 positive, 4 neutral and 1 negative headlines.
Bio-Techne’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Bio-Techne’s market cap is $11.44B at the Nov 13, 2026 close of $72.80, with 157.1M shares outstanding. The shares trade on a P/E ratio of 66.8.
The consensus analyst 12-month price target for Bio-Techne is $70.50, −3.2% from the last close. Of the 3 firms that rated the stock in the last 90 days, 0 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Bio-Techne is overvalued: the Nov 13, 2026 close of $72.80 is 23.4% above Gekko Fair Value of $59.01. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Bio-Techne is expected to report on Feb 2, 2027, before the market opens (79 days away). Analysts expect earnings of $0.47 per share on revenue of $308.7M. Bio-Techne beat the earnings estimate in 6 of its last 8 reports, moving 4.6% on average across the report.
Bio-Techne’s 52-week high is $72.88 and its 52-week low is $43.20; it closed at $72.80 on Nov 13, 2026, +18.6% over the past year. Over the last five years the shares peaked at $130.74 on Dec 31, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.